prodchem
Aug 17, 2026
Eighty five million tons. That is the estimated combined capacity of the newly merged Again and Genomatica to divert carbon dioxide annually, a figure that puts the deal in rare company among carbon utilization platforms. For chemical buyers trying to size up how serious this consolidation really is, that number offers a useful, if imperfect, benchmark.
The figure deserves some unpacking before anyone treats it as a settled fact about current output.
The estimate reflects two very different mechanisms working on opposite ends of the carbon problem. Genomatica's contribution comes from indirect emission avoidance, meaning the potential for its fermentation technology to displace fossil-based chemical production at industrial scale.
Again's contribution works differently. Its plants directly capture CO2 and convert it into acetate and acetic acid on site, avoiding the petrochemical route that would otherwise produce those chemicals.
Two mechanisms, one combined estimate:
Genomatica's side measures potential emissions prevented if its licensed processes replace conventional fossil-based manufacturing at scale.
Again's side measures direct capture, where each ton of product can prevent up to three tons of emissions compared with the petrochemical alternative.
It is worth being precise here. This is not 85 million tons of CO2 already being diverted today. It is an estimated combined capacity, built largely on Genomatica's long-term potential to displace fossil-based chemistry across its licensee network.
Buyers evaluating supplier sustainability claims should treat any large capacity figure the same way. Capacity potential and current throughput are two different things, and procurement teams that conflate them risk overstating what a supplier can deliver right now.
That said, the underlying scale is real. Genomatica's BDO technology already runs at commercial volume, including a Novamont plant in Italy operating since 2016 and a $360 million Qore joint venture plant in Iowa.
Again's own operating numbers are considerably smaller than the headline figure, which is expected for a five-year-old company. Its pilot plant in Copenhagen captures roughly 1 ton of CO2 per day, and its Texas facility scaled that model up using CO2 sourced from a neighboring Dow operation.
A separate demonstration project with Arkema, Johnson Matthey and DSM-Firmenich in Norway is targeted at converting about 9,100 tons of CO2 per year into 4,000 tons of acetone. These are meaningful pilot and early commercial numbers, but they sit well below the tens of millions of tons implied by the combined estimate.
Acetate chemicals produced through this route already have a marketing outlet. Helm has held a 10-year agreement since 2024 to distribute Again's commodity chemicals, including acetic acid and esters.
For procurement teams evaluating bio-based chemical suppliers, the 85 million ton figure is best read as a signal of ambition and technical reach, not an order book.
Practical takeaways for buyers watching this space:
Separate potential from throughput when suppliers quote large capacity or emissions figures, and ask for current production volumes specifically.
Track licensee expansion, since Genomatica's model depends on manufacturers adopting its technology rather than producing directly itself.
Watch acetic acid and acetate pricing as Again's CO2-fed production scales beyond its current pilot and demonstration volumes.
Expect gradual, not immediate, capacity growth, since integrating a legacy licensing business with a young operating company typically takes several years.
Compared with other carbon utilization and biomanufacturing platforms, few combine a proven licensing model with a company actively capturing and converting CO2 on an industrial site. That combination is part of why industry commentary has ranked this deal among the most significant industrial biotechnology consolidations to date.
The 85 million ton estimate will likely keep coming up in comparisons across the sector. Buyers should use it as a starting point for questions, not as a finished answer about current supply.
The headline number is real and worth noting, but it describes potential more than present output. Genomatica's decades of licensing reach combined with Again's direct capture model creates a platform with genuine long-term scale, even if today's actual tonnage remains far smaller.
Procurement teams sourcing acetic acid, acetate derivatives or bio-based BDO should keep this deal on their radar and ask suppliers for concrete current volumes rather than relying on combined capacity estimates alone.
Ready to source glacial acetic acid from verified global suppliers? Explore competitive offers on our platform today.
Featured Product
Found this useful?
Continue Reading
The BIOSECURE Act and associated federal biomanufacturing investment cited in the Again-Genomatica
Genomatica's extensive experimental and scale-up data, spanning nearly 30 years of fermentation process development
The expected August propylene price rise in Asia has modest downstream relevance to polypropylene-based agrochemical packaging costs
